3672

541540

SOLARA

img img img img
No Data Available

SOLARA ACTIVE PHA SCI LTD Share Price Update

As of the latest trading session, SOLARA ACTIVE PHA SCI LTD share price is currently at ₹491.4, which is down by ₹-8.20 from its previous closing. Today, the stock has fluctuated between ₹487.40 and ₹498.10. Over the past year, SOLARA ACTIVE PHA SCI LTD has achieved a return of -0.07%. In the last month alone, the return has been -11.63%.

SOLARA ACTIVE PHA SCI LTD performance

Today’s low

Today’s high

₹ 487.40 ₹ 498.10
₹ 499.60

52 week low

52 week high

₹ 440.20 ₹ 734.40
₹ 499.60

Open Price

₹ 498.10

Prev. Close

₹ 499.60

Volume (Shares)

98574.00

Total traded value

₹ 492.47

Upper Circuit

₹ 599.50

Lower Circuit

₹ 399.70

info

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

SOLARA ACTIVE PHA SCI LTD fundamentals


  • Market cap (Cr)

    1,807.20

  • P/E Ratio (TTM)

    -82.72

  • Beta

    0.93

  • Book Value / share

    345.19

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -17.42

info icon alternate text
  • Market cap (Cr)

    1,768.90

  • P/E Ratio (TTM)

    -82.72

  • Beta

    0.89

  • Book Value / share

    345.19

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -17.42

info icon alternate text

SOLARA ACTIVE PHA SCI LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2025 (Values in Cr)
Revenue 349.00
Operating Expense 359.67
Net Profit -17.42
Net Profit Margin (%) -4.99
Earnings Per Share (EPS) -3.97
EBITDA 30.59
Effective Tax Rate (%) 0.00
Particulars SEP 2025 (Values in Cr)
Revenue 313.54
Operating Expense 324.10
Net Profit -10.08
Net Profit Margin (%) -3.21
Earnings Per Share (EPS) -2.36
EBITDA 35.23
Effective Tax Rate (%) 0.00
Particulars JUN 2025 (Values in Cr)
Revenue 319.15
Operating Expense 309.59
Net Profit 10.53
Net Profit Margin (%) 3.29
Earnings Per Share (EPS) 2.46
EBITDA 58.01
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 273.01
Operating Expense 283.84
Net Profit -4.88
Net Profit Margin (%) -1.78
Earnings Per Share (EPS) -1.65
EBITDA 48.54
Effective Tax Rate (%) 0.00
Particulars DEC 2024 (Values in Cr)
Revenue 300.31
Operating Expense 293.70
Net Profit 8.10
Net Profit Margin (%) 2.69
Earnings Per Share (EPS) 2.47
EBITDA 59.18
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 1283.76
Operating Expense 1293.98
Net Profit -1.08
Net Profit Margin (%) -0.08
Earnings Per Share (EPS) -0.27
EBITDA 212.98
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 1288.92
Operating Expense 1592.98
Net Profit -566.87
Net Profit Margin (%) -43.98
Earnings Per Share (EPS) -157.48
EBITDA -279.33
Effective Tax Rate (%) -16.08
Particulars MAR 2023 (Values in Cr)
Revenue 1443.81
Operating Expense 1510.73
Net Profit -22.21
Net Profit Margin (%) -1.53
Earnings Per Share (EPS) -6.17
EBITDA 156.18
Effective Tax Rate (%) 50.40
Particulars MAR 2022 (Values in Cr)
Revenue 1268.34
Operating Expense 1375.27
Net Profit -58.56
Net Profit Margin (%) -4.61
Earnings Per Share (EPS) -16.29
EBITDA 95.62
Effective Tax Rate (%) 36.11
Particulars MAR 2021 (Values in Cr)
Revenue 1616.88
Operating Expense 1424.33
Net Profit 220.96
Net Profit Margin (%) 13.66
Earnings Per Share (EPS) 68.86
EBITDA 413.74
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share 271.86
ROE % 0.05
ROCE % 5.41
Total Debt to Total Equity 0.89
EBITDA Margin 16.72
Particulars MAR 2024 (Values in Cr)
Book Value / Share 259.42
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.83
EBITDA Margin -7.00
Particulars MAR 2023 (Values in Cr)
Book Value / Share 416.73
ROE % -1.47
ROCE % 1.74
Total Debt to Total Equity 0.68
EBITDA Margin 10.83
Particulars MAR 2022 (Values in Cr)
Book Value / Share 423.57
ROE % -3.74
ROCE % -0.65
Total Debt to Total Equity 0.53
EBITDA Margin 7.61
Particulars MAR 2021 (Values in Cr)
Book Value / Share 442.12
ROE % 16.55
ROCE % 14.72
Total Debt to Total Equity 0.50
EBITDA Margin 25.64
Particulars MAR 2025 (Values in Cr)
Book Value / Share 272.35
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.89
EBITDA Margin 16.59
Particulars MAR 2024 (Values in Cr)
Book Value / Share 260.39
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.83
EBITDA Margin -6.99
Particulars MAR 2023 (Values in Cr)
Book Value / Share 417.54
ROE % -1.47
ROCE % 1.74
Total Debt to Total Equity 0.68
EBITDA Margin 10.82
Particulars MAR 2022 (Values in Cr)
Book Value / Share 424.18
ROE % -3.75
ROCE % -0.67
Total Debt to Total Equity 0.53
EBITDA Margin 7.54
Particulars MAR 2021 (Values in Cr)
Book Value / Share 443.30
ROE % 16.47
ROCE % 14.66
Total Debt to Total Equity 0.50
EBITDA Margin 25.59
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 4.11
Total Assets 2231.84
Total Liabilities 2231.84
Total Equity 1096.91
Share Outstanding 4
Price to Book Ratio 1.88
Return on Assets (%) 0.02
Return on Capital (%) 0.03
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 8.60
Total Assets 2350.96
Total Liabilities 2350.96
Total Equity 936.58
Share Outstanding 3
Price to Book Ratio 1.43
Return on Assets (%) -24.13
Return on Capital (%) -29.31
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 8.89
Total Assets 2899.28
Total Liabilities 2899.28
Total Equity 1502.45
Share Outstanding 3
Price to Book Ratio 0.79
Return on Assets (%) -0.76
Return on Capital (%) -0.89
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 47.25
Total Assets 2944.96
Total Liabilities 2944.96
Total Equity 1527.18
Share Outstanding 3
Price to Book Ratio 1.57
Return on Assets (%) -1.97
Return on Capital (%) -2.28
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 198.54
Total Assets 2613.58
Total Liabilities 2613.58
Total Equity 1592.77
Share Outstanding 3
Price to Book Ratio 3.15
Return on Assets (%) 8.47
Return on Capital (%) 10.07
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 3.97
Total Assets 2225.10
Total Liabilities 2225.10
Total Equity 1096.21
Share Outstanding 4
Price to Book Ratio 1.88
Return on Assets (%) -0.04
Return on Capital (%) -0.06
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 8.48
Total Assets 2346.60
Total Liabilities 2346.60
Total Equity 937.42
Share Outstanding 3
Price to Book Ratio 1.43
Return on Assets (%) -24.15
Return on Capital (%) -29.27
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 8.71
Total Assets 2894.95
Total Liabilities 2894.95
Total Equity 1503.13
Share Outstanding 3
Price to Book Ratio 0.79
Return on Assets (%) -0.76
Return on Capital (%) -0.89
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 47.14
Total Assets 2937.44
Total Liabilities 2937.44
Total Equity 1527.05
Share Outstanding 3
Price to Book Ratio 1.57
Return on Assets (%) -1.99
Return on Capital (%) -2.3
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 198.38
Total Assets 2610.17
Total Liabilities 2610.17
Total Equity 1592.79
Share Outstanding 3
Price to Book Ratio 3.15
Return on Assets (%) 8.46
Return on Capital (%) 10.05
Particulars MAR 2025 (Values in Cr)
Net Income 0.54
Cash from Operations 213.72
Cash from Investing -36.83
Cash from Financing -180.48
Net change in Cash -4.49
Free Cash Flow 253.66
Particulars MAR 2024 (Values in Cr)
Net Income -488.42
Cash from Operations 107.97
Cash from Investing -3.51
Cash from Financing -105.65
Net change in Cash -0.29
Free Cash Flow 149.03
Particulars MAR 2023 (Values in Cr)
Net Income -44.82
Cash from Operations 142.71
Cash from Investing -81.14
Cash from Financing -112.76
Net change in Cash -37.65
Free Cash Flow 254.02
Particulars MAR 2022 (Values in Cr)
Net Income -91.10
Cash from Operations -223.93
Cash from Investing -242.85
Cash from Financing 333.57
Net change in Cash -151.31
Free Cash Flow -15.31
Particulars MAR 2021 (Values in Cr)
Net Income 221.50
Cash from Operations 188.82
Cash from Investing -106.30
Cash from Financing 92.49
Net change in Cash 141.65
Free Cash Flow 363.29
Particulars MAR 2025 (Values in Cr)
Net Income -1.08
Cash from Operations 213.70
Cash from Investing -36.83
Cash from Financing -180.48
Net change in Cash -4.51
Free Cash Flow 253.64
Particulars MAR 2024 (Values in Cr)
Net Income -488.33
Cash from Operations 110.03
Cash from Investing -4.66
Cash from Financing -106.52
Net change in Cash -0.23
Free Cash Flow 153.10
Particulars MAR 2023 (Values in Cr)
Net Income -44.78
Cash from Operations 142.46
Cash from Investing -81.13
Cash from Financing -112.76
Net change in Cash -37.72
Free Cash Flow 253.77
Particulars MAR 2022 (Values in Cr)
Net Income -91.66
Cash from Operations -223.72
Cash from Investing -243.08
Cash from Financing 333.59
Net change in Cash -151.26
Free Cash Flow -14.84
Particulars MAR 2021 (Values in Cr)
Net Income 220.96
Cash from Operations 187.01
Cash from Investing -105.25
Cash from Financing 92.50
Net change in Cash 141.69
Free Cash Flow 360.50
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 28.58 12.37 1.48 219.02 23.12 / 52.00
BLISS GVS PHARMA LTD 217.80 20.82 2.03 2304.08 105.05 / 225.00
CIPLA LTD 1330.85 22.61 3.26 107503.49 1283.00 / 1672.20
FERMENTA BIOTECH LIMITED 310.90 10.34 2.34 915.01 219.00 / 399.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 28.58 23.24 3.98 219.02 23.12 / 52.00
AMRUTAJAN HEALTH LTD 632.15 31.61 5.34 1827.59 548.05 / 789.95
ASTRAZENECA PHARMA IND LT 8878.75 106.70 27.78 22196.88 6501.60 / 10653.05
BLISS GVS PHARMA LTD 217.80 29.67 2.08 2304.08 105.05 / 225.00

SOLARA ACTIVE PHA SCI LTD shareholding pattern

Holding

42.37%
41.99%
11.98%
3.64%
19.94%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

SOLARA ACTIVE PHA SCI LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
499.60 4.07 redarrow
red-green-graph indicator
3 Bearish
13 Bullish
  • 5 Days 492.20
  • 26 Days 516.60
  • 10 Days 497.90
  • 50 Days 534.70
  • 12 Days 500.50
  • 100 Days 556.10
  • 20 Days 510.40
  • 200 Days 568.40
482.42 PIVOT

First Support

474.63

First Resistance

487.83

Second Support

469.22

Second Resistance

495.62

Third Support

461.43

Third Resistance

501.03

RSI

43.75

ADX

41.65

MACD

-16.09

Williams % R

-45.40

Commodity Channel Index (CCI)

-79.10

Date

2026-02-13

Week

81281.00

Same Day

45224.00

Month

41578.00

1 Year

0.93

3 Year

0.97

Over 1 Month

-11.63%

down

Over 1 Year

-0.07%

down

Over 3 Months

-12.45%

down

Over 3 Years

12.12%

down

Over 6 Months

-17.46%

down

Over 5 Years

-18.84%

down

SOLARA ACTIVE PHA SCI LTD Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
18 Aug 2021 3.0 Final 20 Aug 2021 Equity shares
19 Nov 2020 4.0 Interim 20 Nov 2020 Equity shares
28 Jul 2020 2.0 Final 30 Jul 2020 Equity shares
06 Aug 2019 5.0 Final 08 Aug 2019 Equity shares
Dividend date Dividend amount Dividend type Record date Instrument type
18 Aug 2021 3.0 Final 20 Aug 2021 Equity shares
19 Nov 2020 4.0 Interim 20 Nov 2020 Equity shares
28 Jul 2020 2.0 Final 30 Jul 2020 Equity shares
06 Aug 2019 5.0 Final 08 Aug 2019 Equity shares

Top Gainers

Solara Active Pharma Sciences Ltd share result highlights

For Q1 of FY 25-26, the company's consolidated sales were ₹319 crore, and its net profit for the period stood at ₹11 crore. In the corresponding Q1 of FY 24-25, the sales were ₹363 crore with a net loss of ₹13 crore for the period.

Date Source: screener.in, and corporate filings on NSE/BSE

Solara Active Pharma Sciences Ltd share annual reports

For FY 24-25, the company reported consolidated sales of ₹1,284 crore and a net profit of ₹1 crore. In the preceding year, FY 23-24, the company's sales were ₹1,289 crore with the net loss of ₹567 crore.

Date Source: screener.in, and corporate filings on NSE/BSE

Solara Active Pharma Sciences Ltd share dividend

The company's stock has a face value of ₹10.0 per share and pays a dividend yield of 0.00%. The company has not declared any dividend in recent years. The last dividend of ₹3 was issued for FY 2021-22 with an ex-date of August 18, 2021.

Date Source: screener.in, and corporate filings on NSE/BSE

SOLARA ACTIVE PHA SCI LTD Share Price

Solara Active Pharma Sciences Limited was incorporated on February 23, 2017 to undertake business in manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of and dealing in active pharmaceutical ingredients (APIs). The Company has 6 APIs manufacturing plants located in Ambernath, Mangalore, Mysuru, Puducherry, Vishakhapatnam, and Cuddalore with a capacity of over 2,580 kilo litres and two R&D Centres in Chennai and Bengaluru.

The Company offer rich basket of niche high-value products for global markets. The Company has developed 80+ commercial APIs predominantly in anthelmintic, anti-malarias, anti-infective, neuromuscular insomnia and anti-psychotic hyperkalemia segments, among others. These drugs primarily deal with anthelmintic, anti-malarias, beta blockers, muscle relaxants, novel oral anticoagulants, anti-infective and other niche segments.

The Company's manufacturing facilities enjoy regulatory approvals from the United States Food and Drug Administration (USFDA); European Directorate for the Quality of Medicines (EDQM); Korea Food & Drug Administration (KFDA) - South Korea; Euro Zone - Good Manufacturing Practice (EUGMP) - Danish, World Health Organization (WHO) - Geneva; Medicines and Healthcare products Regulatory Agency (MHRA); Federal Commission for the Protection against Sanitary Risk (Cofepris) - Mexico; Therapeutic Goods Administration (TGA) - Australia; Pharmaceuticals and Medical Devices Agency (PMDA) - Japan.

The Company acquired 100% of the equity shares of Strides Chemicals Private Limited and made it the wholly owned subsidiary of the Company effective from September 1, 2018. During the year 2018-19, the Company's wholly owned subsidiary Strides Chemicals Private Limited amalgamated with the Company on December 20, 2019 and the merger was given effect in February, 2020.

The Company's new Greenfield plant situated at SEZ unit, Plot No.:3B,3C,3D, Part 2 and 2A-1, APIIC APSEZ, Atchutapuram Village, Rambilli Mandal, Visakhapatnam - 531011, Andhra Pradesh, commenced commercial production in 2021.

The Company acquired 487000 additional stake in Sequent Penems Private Limited, subsidiary company and subsequently Sequent Pharma became the wholly owned subsidiary of Company effective from April 27, 2021. In 2024, the Company sold its entire shareholding in Sequent Penems Private Limited to Symbio Generrics India Private Limited and Sequent Penems Private Limited ceased to be a subsidiary of the Company with effect from April 25, 2024.

The wholly owned entity, Synthix Global Pharma Solutions Limited has got incorporated on April 29, 2025.





.

Parent organization Indian Private
NSE symbol SOLARA
Founded 2017
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Solara Active Pharma Sciences Ltd?

Answer Field

Solara Active Pharma Sciences Ltd share price is for NSE ₹ 491.40 & for BSE ₹ 492.00 as on Feb 16 2026 10:21 AM.

What is the Market Cap of Solara Active Pharma Sciences Ltd Share?

Answer Field

The market cap of Solara Active Pharma Sciences Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Feb 16 2026 10:21 AM.

What is the 52 Week High and Low of Solara Active Pharma Sciences Ltd?

Answer Field

The 52 Week High and Low of Solara Active Pharma Sciences Ltd for NSE is ₹ 734.40 and ₹ 440.20 and for BSE is ₹ 734.20 and ₹ 441.00.

What is 1 year return for Solara Active Pharma Sciences Ltd?

Answer Field

The 1 year returns on the stock has been -0.07%.

What is the P/E Ratio of Solara Active Pharma Sciences Ltd Share?

Answer Field

As on Feb 16 2026 10:21 AM the price-to-earnings (PE) ratio for Solara Active Pharma Sciences Ltd share is -82.72.

What is the PB ratio of Solara Active Pharma Sciences Ltd Share?

Answer Field

As on Feb 16 2026 10:21 AM, the price-to-book (PB) ratio for Solara Active Pharma Sciences Ltd share is 345.19.

How to Buy Solara Active Pharma Sciences Ltd Share?

Answer Field

You can trade in Solara Active Pharma Sciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Solara Active Pharma Sciences Ltd Share on Bajaj Broking App?

Answer Field

To buy Solara Active Pharma Sciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Solara Active Pharma Sciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Solara Active Pharma Sciences Ltd?

Answer Field

The CEO of Solara Active Pharma Sciences Ltd is Poorvank Purohit, who also serves as the Managing Director of the company.

When was Solara Active Pharma Sciences Ltd established?

Answer Field

Solara Active Pharma Sciences Ltd was incorporated on February 23, 2017. The company was formed from the demerger of the Active Pharmaceutical Ingredients (API) business from Strides Shasun Ltd.

What factors influence the Solara Share Price?

Answer Field

The Solara share price is influenced by factors such as financial performance, market conditions, regulatory approvals, and the global demand for active pharmaceutical ingredients. Changes in debt levels, profit margins, and strategic moves like the sale of its stake in Sequent Penems also impact its share price.

Is Solara Active Pharma Sciences Ltd debt-free?

Answer Field

No, Solara Active Pharma Sciences Ltd is not debt-free. As of March 2024, the company reported borrowings of Rs. 1,012 crores. However, it has been actively working to reduce its working capital requirements over time.

What is the CAGR of Solara Share?

Answer Field

The Compound Annual Growth Rate (CAGR) of Solara’s stock price over the past five years stands at 13%. However, the three-year CAGR is negative at -7%, reflecting a decline in the stock’s value during that period.

How has the Solara Share Price performed over the past year?

Answer Field

Over the past year, Solara’s share price has seen a significant increase, rising by 143%, demonstrating a positive market response despite challenges in revenue and profitability.

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59